Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.
Read more about the analysis here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.